Nashik: The state government has chosen two North Maharashtra Regency – Nashik and Jalgaon – to launch Zydus Cadila Covid-19 vaccine three doses of Zycov-D on the pilot base.
This center has recently announced that this vaccine will initially be introduced in seven states, including Maharashtra.
This vaccine is given using a needle-free applicator.
Deputy State Director of the Ministry of Health (Nashik Region) Dr.
Pd Gandal confirmed that the ZYCOV-D vaccine would be given to beneficiaries who were not vaccinated by 18 years and above in the two districts, although the date of the launch had not been off by the state government.
“Health workers, who will be involved in inoculation with this new vaccine, will provide training before the launch,” he added.
The training session for HCW has been planned in two districts on Wednesday.
The state government, in relation to WHO representatives, will conduct training on various aspects of vaccines before the formal launch of the program.
Commissioner of Municipal Nashik Kailas Jadhav and Jalgaon District Collector Abhijit Raut said the dosage of the two districts had not been carried out.
“The two districts have been chosen to further increase vaccine coverage.
The Civic body will plan centers where new vaccines will be available for beneficiaries in time,” Jadhav said.
Raut said Jalgaon’s government thought to introduce a new vaccine in the centers where the number of beneficiaries were not vaccinated more than 100.
“We expect vaccine allotment in the next few days,” added Raut.
At present, Covishield, Covaxin and Sputnik V vaccines are available in this region.
According to the data of the Ministry of Health, the number of beneficiaries (18 years and above) in Nashik more than 51 lakh and in Jalgaon, it was more than 34 lakh.
Until the end of November, the first dose of Covid vaccine was given to more than 73% of beneficiaries in Nashik and more than 68% in Jalgaon.
The beneficiaries of choosing Zycov-D must take three doses, the second one after 28 days and the third after 56 days.
“The Zycov-D vaccine will be given to beneficiaries that are not vaccinated,” the official said.
In May and June this year, Zydus Cadila, in relation to the HCG Manavata Cancer Center based in Nashik, has conducted Zycov-D clinical trials in 300 children in the age group 12-17 years, and 1,000 adults in Nashik.
Current trials with no children who report bad events after immunization.